Literature DB >> 2344034

The urea cycle in the Rett syndrome.

S Thomas1, V Oberholzer, J Wilson, M Hjelm.   

Abstract

The in vivo functioning of the urea cycle in the Rett syndrome (RS) was investigated using alanine load test. The test was carried out in girls with RS and their mothers. These results were compared with those on normal females, males and obligate carriers for ornithine carbamoyltransferase deficiency. Post load hyperammonaemia was not seen in any of the RS girls who were not on medication (valproate). Increased orotate excretion was found in some of the RS girls and mothers. The pattern of urinary excretion of orotate in RS girls and their mothers after a standardised alanine load was similar to that found in female carriers of OCT deficiency. This finding can be explained by a mutant OCT, subject to the Lyon effect, and linked to the gene abnormality in RS or by the presence of an abnormal X-linked mitochondrial protein synthesised in cytoplasma and positioned in close proximity to OCT. Such a protein abnormality could also affect mitochondrial functions in other cells, e.g. in the developing brain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2344034     DOI: 10.1016/s0387-7604(12)80186-0

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  4 in total

1.  Modelling amino acid metabolism.

Authors:  M Hjelm; J Seakins
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

Review 2.  Rett syndrome.

Authors:  A Clarke
Journal:  J Med Genet       Date:  1996-08       Impact factor: 6.318

3.  the allopurinol test in patients with Rett syndrome.

Authors:  M Pineda; M A Vilaseca; A Vernet; J Campistol; A Mas; C Fabrega
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

4.  X chromosome linkage studies in familial Rett syndrome.

Authors:  A R Curtis; S Headland; S Lindsay; N S Thomas; E Boye; S Kamakari; P Roustan; M Anvret; J Wahlstrom; G McCarthy
Journal:  Hum Genet       Date:  1993-01       Impact factor: 4.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.